We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Articles

Results 1 to 5 of 601
Most popular |Most recent


Learning the Steps of the BPCIA's Patent Dance : notice of commercial marketing is mandatory

USA - September 30 2016 The Federal Circuit’s second opinion interpreting the Biologics Act in Amgen v. Apotex is dense, but the outcome is simple. There are two takeaways...

Jamie Kitano, Peter Strand.

Ranbaxy loses FDA approval for two generics

USA, India - November 13 2014 According to a statement that Ranbaxy Laboratories Ltd. provided to the Bombay Stock Exchange Website, the U.S. Food and Drug Administration (FDA)...

Madeleine M. McDonough, Chris A. Johnson, Debra S. Dunne, John Simpson.

Dissatisfied patent reexamination plaintiff contends standing conferred by statute

USA - November 13 2014 A consumer-interest organization that was dissatisfied by a Board of Patent Appeals and Interferences (BPAI) ruling in the appeal of a patent...

Madeleine M. McDonough, Chris A. Johnson, Debra S. Dunne, John Simpson.

FTC settles deceptive sales-tactics claims against MPHJ Technology

USA - November 13 2014 The U.S. Federal Trade Commission (FTC) has agreed to settle claims that MPHJ Technology Investments, LLCa patent-assertion entity (PAE)and company...

Madeleine M. McDonough, Chris A. Johnson, Debra S. Dunne, John Simpson.

News bytes

USA - November 13 2014 The U.S. Food and Drug Administration (FDA) makes available Guidance for Industry and staff titled "Molecular Diagnostic Instruments with Combined...

Madeleine M. McDonough, Chris A. Johnson, Debra S. Dunne, John Simpson.